Biosimilars - The Future Transformation of Product Exclusivity in the Biotechnology Arena
The nature of biotechnology has, up until recently, prevented the threat of generic intrusion on product sales. Biologics are difficult to replicate compared to small molecules and even slight differences in manufacturing processes could lead to significant clinical differences.
View full press release